📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Medanta Shareholders Approve Key Director Appointments with Over 99% Majority
Global Health Limited (Medanta) has successfully passed three resolutions via postal ballot with overwhelming shareholder support. Dr. Ravi Gupta and Mr. Rajan Bharti Mittal were re-appointed as Independent Directors, receiving 99.64% and 99.65% of votes in favor, respectively. Furthermore, Ms. Shonan Purie Trehan was appointed as a Non-Executive Non-Independent Director with 99.82% approval. The high participation and near-unanimous voting from institutional and public shareholders reflect strong confidence in the company's governance.
Key Highlights
Resolution for Dr. Ravi Gupta's re-appointment passed with 99.6383% votes in favor.
Mr. Rajan Bharti Mittal's re-appointment as Independent Director secured 99.6517% approval.
Appointment of Ms. Shonan Purie Trehan as Non-Executive Director passed with 99.8236% support.
Total valid votes cast amounted to 24,12,94,677, representing high shareholder engagement across promoter and public categories.
💼 Action for Investors
The overwhelming support for these appointments indicates strong institutional trust in Medanta's leadership. Investors can remain confident in the company's stable governance and continuity of its strategic direction.
Medanta Q3 FY26: Revenue Grows 19% to Rs 1,143 Cr; Noida Ramp-up Impacts Margins
Global Health Limited (Medanta) reported a robust 19% YoY revenue growth to Rs 11,428 million for Q3 FY26, driven by strong performance across its hospital network. While core EBITDA margins (excluding Noida) remained healthy at 25.4%, consolidated margins were pressured to 21.8% due to a Rs 320 million operating loss from the newly commissioned Noida facility. Reported PAT of Rs 950 million was impacted by a one-time exceptional labor code charge of Rs 366 million, though adjusted PAT stood higher at Rs 1,224 million. Operational metrics remained strong with ARPOB increasing 10% YoY to Rs 67,361.
Key Highlights
Total income rose 19% YoY to Rs 11,428 million; Adjusted PAT stood at Rs 1,224 million excluding one-time items.
ARPOB increased by 10% YoY to Rs 67,361, while Average Length of Stay (ALOS) improved by 7% to 3.02 days.
International patient revenue grew significantly by 30% YoY to Rs 703 million.
Noida facility completed its first full quarter with Rs 343 million revenue and expanded to 328 beds.
Developing hospitals (Lucknow and Patna) delivered 22% revenue growth with strong EBITDA margins of 31.7%.
💼 Action for Investors
Investors should focus on the pace of the Noida facility's EBITDA breakeven and the execution of the 496-bed brownfield expansion pipeline. The stock remains a solid play on premium healthcare, but short-term margins will be influenced by the gestation period of new units.
Medanta Q3 FY26: Revenue Grows 19% to ₹1,143 Cr; PAT Impacted by Noida Launch and Labour Code Costs
Global Health (Medanta) reported a strong 19.1% y-o-y revenue growth for Q3 FY26, reaching INR 11,428 million, driven by robust patient volumes and a 9.9% increase in ARPOB. However, reported PAT declined 33.5% y-o-y to INR 950 million, primarily due to initial operating losses and depreciation from the new Noida facility, alongside a one-time exceptional charge of INR 366 million for new Labour Code compliance. Excluding the Noida unit, EBITDA grew by 10.9%, demonstrating healthy core performance across matured and developing hospitals. The company continues its aggressive expansion, adding 144 beds during the quarter and planning a new 750-bed facility in Delhi.
Key Highlights
Total Income rose 19.1% y-o-y to INR 11,428 million, supported by a 14.3% growth in In-patient volumes.
ARPOB increased 9.9% y-o-y to INR 67,361, while Average Length of Stay (ALOS) improved by 6.6% to 3.02 days.
The newly launched Noida hospital reported a revenue of INR 343 million but incurred an EBITDA loss of INR 320 million.
A non-recurring exceptional item of INR 366 million was recorded due to the statutory impact of new Labour Codes.
International patient revenue grew significantly by 29.9% y-o-y, reaching INR 703 million.
💼 Action for Investors
Investors should look past the temporary PAT decline caused by one-off costs and the Noida scale-up phase, focusing instead on the strong 19% top-line growth and improving operational metrics. Monitor the Noida facility's path to EBITDA break-even as a key catalyst for margin recovery in upcoming quarters.
Medanta Q3 FY26: Total Income up 19% to INR 11,428 Mn; PAT hit by Noida launch & one-time costs
Global Health (Medanta) reported a 19.1% YoY increase in total income to INR 11,428 million for Q3 FY26, driven by strong volume growth and higher realizations. Consolidated PAT declined 33.5% YoY to INR 950 million, significantly impacted by a non-recurring exceptional item of INR 366 million related to new Labour Codes and initial losses from the Noida facility. Operational efficiency improved with ARPOB rising 9.9% to INR 67,361 and inpatient counts up 14.3%. The new Noida hospital is scaling up, contributing INR 343 million in revenue while still in its gestation phase.
Key Highlights
Total Income rose 19.1% YoY to INR 11,428 million; 9M FY26 income up 17.6% to INR 33,131 million.
ARPOB grew 9.9% YoY to INR 67,361, while In-patient and Out-patient counts rose 14.3% and 19.5% respectively.
PAT fell 33.5% YoY to INR 950 million due to a INR 366 million exceptional labor code charge and Noida startup costs.
Medanta Noida reported its first full quarter with INR 343 million revenue and an EBITDA loss of INR 320 million.
Developing hospitals (ex-Noida) showed strong performance with 21.5% revenue growth and 31.7% EBITDA margins.
💼 Action for Investors
Investors should focus on the robust top-line growth and operational metrics like ARPOB, as the PAT decline is largely due to non-recurring items and planned expansion gestation. Monitor the ramp-up and EBITDA breakeven timeline of the Noida facility.
Medanta Q3 Revenue Up 15.7% YoY to ₹9,402 Mn; PAT Impacted by ₹352 Mn Exceptional Charge
Global Health Limited (Medanta) reported a 15.7% YoY increase in revenue from operations to ₹9,401.65 million for Q3 FY26. However, Profit After Tax (PAT) declined to ₹799.07 million from ₹1,313.86 million in the previous year's restated quarter, primarily due to a ₹352 million exceptional charge related to new Labour Codes. The company also announced management changes, including the appointment of Malik Mohd. Ashhab as Head of Diagnostic Services. While top-line growth remains healthy, operational expenses, particularly employee benefits and consultant fees, saw a notable increase during the period.
Key Highlights
Revenue from operations grew 15.7% YoY to ₹9,401.65 million in Q3 FY26 compared to ₹8,123.67 million in Q3 FY25.
Profit After Tax (PAT) stood at ₹799.07 million, significantly impacted by a ₹352 million exceptional item for Labour Code compliance.
Employee benefit expenses rose 36% YoY to ₹2,523 million, reflecting increased staffing and potential wage adjustments.
Malik Mohd. Ashhab appointed as Head-Diagnostic Services to strengthen the senior management team.
Board recommended the re-appointment of Independent Directors Dr. Ravi Gupta and Mr. Rajan Bharti Mittal for second 5-year terms.
💼 Action for Investors
Investors should look through the one-time exceptional hit to PAT and focus on the robust 15%+ revenue growth. It is important to monitor if the rising employee and consultancy costs are structural or temporary to assess long-term margin stability.
Medanta Q3 Revenue Rises 15.7% to ₹9,402 Mn; PAT Impacted by Exceptional Labour Code Costs
Global Health Limited (Medanta) reported a steady 15.7% YoY revenue growth for Q3 FY26, reaching ₹9,401.65 million. However, Net Profit (PAT) for the quarter declined to ₹799.07 million from ₹1,313.86 million (restated) in the previous year, primarily due to a one-time exceptional charge of ₹352 million related to new Labour Codes. On a nine-month basis, the company remains profitable with a PAT of ₹3,720.70 million. The board also strengthened leadership by appointing a new Head of Diagnostic Services and re-appointing two key Independent Directors.
Key Highlights
Revenue from operations grew 15.7% YoY to ₹9,401.65 million in Q3 FY26 compared to ₹8,123.67 million (restated) in Q3 FY25.
Profit After Tax (PAT) stood at ₹799.07 million, significantly impacted by a ₹352 million exceptional expense for Labour Code provisions.
Nine-month (9M FY26) revenue reached ₹27,487.49 million, showing healthy growth over the ₹24,012.78 million recorded in the same period last year.
Mr. Malik Mohd. Ashhab appointed as Head-Diagnostic Services to lead the company's diagnostic segment expansion.
Dr. Ravi Gupta and Mr. Rajan Bharti Mittal re-appointed as Independent Directors for a second 5-year term starting July 2026.
💼 Action for Investors
Investors should focus on the robust double-digit revenue growth while treating the PAT decline as a largely one-time accounting adjustment due to labour code provisions. Monitor the performance of the diagnostic services segment under new leadership for future margin improvements.
Medanta Q3 Revenue Up 15.7% YoY to ₹9,402 Mn; PAT Declines on Exceptional Costs
Global Health Limited (Medanta) reported a steady 15.7% YoY growth in standalone revenue for Q3 FY26, reaching ₹9,401.65 million. However, Profit After Tax (PAT) saw a significant decline to ₹799.07 million from ₹1,313.86 million in the year-ago period (restated). This profitability hit was largely due to a ₹352 million exceptional expense related to new Labour Codes and a sharp rise in employee benefit expenses and consultancy fees. The company also strengthened its leadership by appointing a new Head of Diagnostic Services.
Key Highlights
Revenue from operations increased 15.7% YoY to ₹9,401.65 million from ₹8,123.67 million.
Standalone Profit After Tax (PAT) dropped 39% YoY to ₹799.07 million.
Exceptional item of ₹352 million recognized in Q3 FY26 due to the impact of new Labour Codes.
Employee benefit expenses rose significantly to ₹2,523 million compared to ₹1,850 million in Q3 FY25.
Appointment of Mr. Malik Mohd. Ashhab as Head-Diagnostic Services to lead the diagnostics vertical.
💼 Action for Investors
Investors should be cautious as rising operating costs (employee and consultancy fees) are currently compressing margins despite healthy revenue growth. Monitor management's commentary on whether the Labour Code impact is a one-time hit or will lead to sustained higher personnel costs.
Medanta (Global Health) Long-Term Credit Rating Upgraded to CRISIL AA/Stable
CRISIL Ratings has upgraded the long-term credit rating of Global Health Limited (Medanta) to 'CRISIL AA/Stable' from 'CRISIL AA-/Positive'. This upgrade applies to bank loan facilities totaling Rs. 1,500 crore, including Rs. 1,110 crore in term loans and Rs. 390 crore in working capital facilities. The short-term rating has been reaffirmed at 'CRISIL A1+', the highest possible rating for short-term debt. This revision reflects the company's robust financial health and consistent operational performance in the healthcare sector.
Key Highlights
Long-term rating upgraded to CRISIL AA/Stable for Rs. 1,500 crore bank facilities.
Short-term rating reaffirmed at CRISIL A1+, indicating strong liquidity and low credit risk.
Rated facilities include Rs. 610 crore in proposed term loans and Rs. 500 crore in existing term loans from SBI and ICICI.
Working capital facilities totaling Rs. 390 crore from major banks like HDFC, SBI, and ICICI were also covered.
The upgrade from 'Positive' outlook to 'Stable' rating signifies a sustained improvement in credit profile.
💼 Action for Investors
The credit upgrade is a positive signal of Medanta's strengthening balance sheet and may lead to lower borrowing costs in the future. Investors should view this as a validation of the company's operational stability and financial discipline.